Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection

Bini, Edmund J.; Bräu, Norbert; Sue Currie; Hui Shen; Anand, Bhupinderjit S.; Ke-Qin Hu; Lennox Jeffers; Ho, Samuel B.; Johnson, David; Schmidt, Warren N.; King, Paul; Ramsey Cheung; Morgan, Timothy R.; Awad, Joseph; Pedrosa, Marcos; Kyong-Mi Chang; Aytaman, Ayse; Simon, Franz; Hagedorn, Curt; Moseley, Richard
August 2005
American Journal of Gastroenterology;Aug2005, Vol. 100 Issue 8, p1772
Academic Journal
BACKGROUND: Many veterans may not be candidates for hepatitis C virus (HCV) treatment due to contraindications to therapy. The aims of this study were to determine the proportion of HCV-infected veterans who were eligible for interferon alfa and ribavirin therapy and to evaluate barriers to HCV treatment. METHODS: We prospectively enrolled 4,084 veterans who were referred for HCV treatment over a 1-yr period at 24 Veterans Affairs (VA) Medical Centers. Treatment candidacy was assessed using standardized criteria and the opinion of the treating clinician. RESULTS: Overall, 32.2% (95% CI, 30.8–33.7%) were candidates for HCV treatment according to standardized criteria, whereas 40.7% (95% CI, 39.2–42.3%) were candidates in the opinion of the treating clinician. Multivariable analysis identified ongoing substance abuse (OR = 17.68; 95% CI, 12.24–25.53), comorbid medical disease (OR = 9.62; 95% CI, 6.85–13.50), psychiatric disease (OR = 9.45; 95% CI, 6.70–13.32), and advanced liver disease (OR = 8.43; 95% CI, 4.42–16.06) as the strongest predictors of not being a treatment candidate. Among patients who were considered treatment candidates, 76.2% (95% CI, 74.0–78.3%) agreed to be treated and multivariable analysis showed that persons ≥50 yr of age (OR = 1.37; 95% CI, 1.07–1.76) and those with >50 lifetime sexual partners (OR = 1.44; 95% CI, 1.08–1.93) were more likely to decline treatment. CONCLUSIONS: The majority of veteran patients are not suitable candidates for HCV treatment because of substance abuse, psychiatric disease, and comorbid medical disease, and many who are candidates decline therapy. Multidisciplinary collaboration is needed to overcome barriers to HCV therapy in this population. (Am J Gastroenterol 2005;100:1–8)


Related Articles

  • Synthesis and antiviral activity of 4-quinolinecarboxylic acid hydrazides. Zemtsova, M. N.; Zimichev, A. V.; Trakhtenberg, P. L.; Belen'kaya, R. S.; Boreko, E. I. // Pharmaceutical Chemistry Journal;Oct2008, Vol. 42 Issue 10, p571 

    Antiviral agents were sought by using ethyl esters of 2-R-4-quinolinecarboxylic acids to synthesize the corresponding aryl (heteryl) hydrazides. 2-Methyl-4-quinolinecarboxylic acid hydrazide was used to synthesize vinylogs containing a nitro group in the substituent. The resulting compounds were...

  • Isotope Exchange of Azidothymidine with Tritium. Sidorov, G. V.; Zverkov, Yu. B.; Myasoedov, N. F. // Radiochemistry;Jan/Feb2003, Vol. 45 Issue 1, p87 

    The following modes of isotope exchange of azidothymidine (3'-azido-3'-deoxythymidine) with tritium were studied: solid- and liquid-phase isotope exchange with gaseous tritium and isotope exchange in solution with tritium water. Catalytic reactions of azidothymidine with gaseous tritium in...

  • Viral Load Testing in Resource-Limited Settings. Schooley, Robert T. // Clinical Infectious Diseases;1/1/2007, Vol. 44 Issue 1, p139 

    The article focuses on the issues regarding availability of the impact of antiretroviral therapy on HIV-associated morbidity and mortality. These aspects had been one of the most dramatic examples of the benefits that accrue from investment in the academic and industrial biomedical research...

  • Search for Antiviral Agents Among Quinopimaric Acid Scaffold Derivatives. Vafina, G.; Uzbekov, A.; Zarubaev, V.; Karpinskaya, L.; Shtro, A.; Yunusov, M. // Chemistry of Natural Compounds;Jan2015, Vol. 51 Issue 1, p103 

    Novel quinopimaric acid scaffold derivatives were synthesized. Their antiviral activity against influenza A/California/07/09 (H1N1) was studied. It was found that several of the synthesized quinopimaric acid scaffold derivatives were potentially active etiotropic antiviral compounds.

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Oct2004, Vol. 18 Issue 10, p614 

    Present abstracts of several research on antiviral agents. HIV replication capacity to gauge viral fitness as a predict of progression to clinical AIDS; Insights on how HIV evades eradication; Impact of micronutrients on the survival of HIV patients.

  • Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients. C. Herzmann; Z. Cuthbertson; L. Fosdick; M. Fisher; M. Nelson; N. Perry; M. Law; H. Wand; G. Janossy; M. A. Johnson; M. Youle // Journal of Antimicrobial Chemotherapy (JAC);Sep2008, Vol. 62 Issue 3, p583 

    : Objectives Subcutaneous administration of interleukin-2 (IL-2) has been shown to increase CD4 counts in HIV-infected patients. It remains unclear whether this effect is associated with a clinical benefit. : Patients and methods We conducted a long-term follow-up in the cohort of the...

  • CycloSal-Pronucleotides of Brivudine Monophosphate - Highly Active Antiviral Agents. Meier, Chris; Meerbach, Astrid; Wutzler, Peter // Current Medicinal Chemistry - Anti-Infective Agents;Oct2005, Vol. 4 Issue 4, p317 

    CycloSal-BVDUMP triesters 32-34 5-[(E)-2-bromovinyl]-2'-deoxyuridine (BVDU 2) have been studied with regard to their potential anti-EBV activity. In addition to the 3'-unmodified cycloSal-BVDUMP triesters 32a-f, the 3'- hydroxyl function has been esterified with different aliphatic carboxylic...

  • Less Than 95% Adherence to Nonnucleoside Reverse-Transcriptase Inhibitor Therapy Can Lead to Viral Suppression. Bangsberg, David R. // Clinical Infectious Diseases;10/1/2006, Vol. 43 Issue 7, p939 

    For antiretroviral therapy, the 95% adherence ‘threshold’ is based on nucloside-exposed patients who are receiving partially suppressive, unboosted protease inhibitor regimens. Using unannounced pill counts and electronic medication monitoring, viral suppression is common with a...

  • Complete Cure of Persistent Virus Infections by Antiviral siRNAs. Saulnier, Aure; Pelletier, Isabelle; Labadie, Karine; Colbère-Garapin, Florence // Molecular Therapy;Jan2006, Vol. 13 Issue 1, p142 

    Small interfering RNAs (siRNAs) have been developed as antiviral agents for mammalian cells. The capacity of specific siRNAs to prevent virus infections has been demonstrated, and there is evidence that these new antiviral agents could have a partial therapeutic effect a few days after...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics